Skip to main content

Co-Diagnostics, Promega Ink Manufacturing Deal for Coronavirus Test

NEW YORK — Co-Diagnostics said on Tuesday that it has signed a manufacturing agreement for its Logix Smart COVID-19 test with Promega for additional production capacity.

Co-Diagnostics' test uses the company's CoPrimer technology to detect the RdRp gene of the SARS-CoV-2 virus. It received Emergency Use Authorization from the US Food and Drug Administration earlier this month and CE-IVD marking in February.

Wisconsin-based Promega will begin manufacture of the tests immediately. Additional terms were not disclosed.

Salt Lake City, Utah-based Co-Diagnostics said that the arrangement will help it meet demand for the Logix Smart test as it increases its outreach efforts to public and private labs in the US.